In:
International Journal of Cancer, Wiley, Vol. 135, No. 5 ( 2014-09), p. 1132-1141
Abstract:
What's new? Multiple myeloma is currently not curable, and often recurs. New tactics to combat this disease are sorely needed. This study asked whether monoclonal antibodies could do the trick. The authors targeted a cell surface protein, β 2 ‐Microglobulin, which is present in higher concentration in myeloma cells. They showed that mAbs against β 2 ‐Microglobulin could direct the cell‐destroying power of NK cells toward the cancer cells without harming normal cells. Addition of the drug lenalidomide, which is used to treat multiple myeloma, enhanced this attack, suggesting these antibodies could provide a useful treatment for MM patients.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink